Evidence map›Paper›PMID 41439273›Full record

ReviewElectrophoresis2026

Sustainability in Analytical Chemistry Illustrated by Pharmaceutical Nitrosamine Testing.

Felix Bredendiek, Sebastian Schmidtsdorff, Maria Kristina Parr

Abstract readReview
In one paragraph

Review in Electrophoresis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Felix BredendiekDepartment of Biology, Chemistry, Pharmacy, Institute of Pharmacy, Freie Universität Berlin, Berlin, Germany.
Sebastian SchmidtsdorffDepartment Risk Communication, German Federal Institute for Risk Assessment, GLP Federal Bureau, Berlin, Germany.
Maria Kristina ParrDepartment of Biology, Chemistry, Pharmacy, Institute of Pharmacy, Freie Universität Berlin, Berlin, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Following the valsartan scandal in 2018, the testing of drug substances and drug products for N-nitrosamines has become a critical and mandatory quality control measure. The European Pharmacopoeia chapter 2.5.42 currently describes three analytical methods for this purpose: HPLC-MS/MS, GC-MS, and GC-MS/MS. The US Pharmacopeia monograph 〈1469〉 adds four other methods, LC-high-resolution mass spectrometry (HRMS), headspace GC-MS, LC-MS/MS, and GC-MS/MS. In addition, our group has developed a universal method on the basis of supercritical fluid chromatography (SFC), capable of separating 16 different N-nitrosamines within just 4 min. These eight methods differ significantly in terms of sustainability, with particular emphasis on the reagents used, the separation techniques employed, and their performance characteristics. When assessing the sustainability of such analytical methods, it is essential to consider not only ecological but also economic factors.

Indexed as

NitrosaminesChromatography, High Pressure LiquidChromatography, Supercritical FluidGas Chromatography-Mass SpectrometryPharmaceutical PreparationsTandem Mass SpectrometryNitrosaminesPharmaceutical Preparationsgas chromatography (GC)green chemistryHPLCMSN‐nitrosaminessupercritical fluid chromatography (SFC)sustainability

Identifiers

PMID41439273
PMCPMC12905522

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.